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ABSTRACT:  To investigate the possible involvement of T-lymphocytes in the
immunopathogenesis of idiopathic eosinophilic pneumonia (IEP), we have evalu-
ated the phenotypic characteristics both of peripheral blood and alveolar lympho-
cytes in six patients with symptomatic IEP, and in 24 healthy nonsmokers as controls,
by employing bronchoalveolar lavage (BAL), monoclonal antibodies, and flow-
cytometry.
In IEP, total and differential cell counts showed a mild alveolitis with an increase
of eosinophil percentage and number; the alveolar lymphocyte count was also
increased.  In BAL, the total number both of CD4+ and CD8+ lymphocytes was
significantly raised; CD4+ cells expressed early (CD25) activation antigens.  The
analysis of CD45R0, CD45RA and CD62L coexpression in IEP patients, when com-
pared to healthy controls, revealed an accumulation of alveolar CD4+ cells show-
ing phenotypic repertoire usually expressed by memory T-cells (CD45R0+, CD45RA-,
CD62L-).  CD8+ alveolar lymphocytes did not show any significant increase of acti-
vation antigen coexpression.  Circulating lymphocytes were not significantly increased
and showed only a significantly higher CD25 expression.
These data suggest that a pivotal role is played by activated and memory CD4+
alveolar lymphocytes in IEP patients.
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Eosinophilic lung disorders are characterized by the
accumulation of eosinophil leucocytes in pulmonary struc-
tures (alveolar spaces, interstitium) and, frequently, also
in the peripheral blood [1].  In patients with idiopathic
eosinophilic pneumonia (IEP), bronchoalveolar lavage
(BAL) shows an increase of the total cell count, with a
marked increase of eosinophils; the percentage of macro-
phages is consequently reduced, whereas lymphocytes
do not show significant changes [1].  Eosinophilic lung
disorders include Loeffler's syndrome [2], Aspergillus
infection [3], eosinophilic pneumonia in bronchial asthma
[4], drug-induced pneumonia [5], tropical eosinophilia [6],
chronic eosinophilic pneumonia [7], acute eosinophilic
pneumonia with respiratory failure [8], Churg-Strauss syn-
drome [9], and idiopathic eosinophilic pneumonia [10].
Mechanisms leading to the parenchymal injury in these
diseases are mainly mediated by factors contained in
eosinophil granules [11].  Some useful information on
the immunopathogenesis of idiopathic eosinophilic lung
disease could be obtained by the analysis of processes
physiologically involved in eosinophil maturation and
traffic. In fact, in normal conditions, lymphocytes, recru-
ited and activated by antigen-presenting cells, release
lymphokines, such as interleukin-3 (IL-3) [12] granulo-
cyte/macrophage colony-stimulating factor (GM-CSF)
[13], interleukin-4 (IL-4) [14] and interleukin-5 (IL-5)
[13, 15], regulating eosinophil differentiation, matura-
tion, proliferation, recruitment and activation [16].  These
physiological activities, if upregulated, may have a cen-
tral role in the modulation of eosinophil-mediated tissue
damage within the alveolar microenvironment [17].  On
the other hand, the accumulation of eosinophils in the
lung, observed in experimental conditions in mice, appears
to be lymphocyte-dependent, mast-cell-independent and
mainly IL-5 mediated [15].  The aim of this study was
to investigate a possible involvement of T-lymphocytes
in the pathogenesis of IEP [18], by employing BAL,
monoclonal antibodies and flow-cytometry.
Patients and methods
Study population
Six symptomatic patients with IEP were studied.  They
included two males and four females, aged 37–58 yrs
(mean±SD 43±9 yrs, one smoker and five nonsmokers).
Diagnosis, in all patients, was made on the basis of
clinical, laboratory and chest radiographic data, and was
confirmed by histological findings on specimens from
transbronchial lung biopsies performed during bron-
choscopy, after bronchoalveolar lavage, in the same lung
lobe or segment showing radiological abnormalities.
Histological analysis showed eosinophilic infiltration of
lung parenchyma without vasculitis, fibrosis, granulomas
or necrosis; no evident increase of either S100 + or CD1+
cell was found either in tissues or in BAL.  No parasitic
infestation, exposure to chemicals, concomitant infec-
tion, drug intake or abnormal immunoglobulin E (IgE)
levels were present in the population studied.  No patient
had a medical history of asthma, and pulmonary func-
tion tests excluded actual obstruction; in all cases, the
disease was symptomatic (fever, cough, dyspnoea); elev-
ation of erythrocyte sedimentation rate and resting hypox-
aemia were evident (arterial oxygen tension (Pa,O2) <8
kPa).  All patients studied had abnormal chest radio-
graphs, showing peripheral nonsegmental infiltrates.  In
two patients, the clinical presentation was acute (disease
duration 1–4 weeks), and in four it was subacute or chron-
ic (disease duration more than 12 weeks).  No patients
had received steroids or any other therapy at the time of
the study, and all showed a dramatic improvement of
clinical signs and symptoms, and of radiological opaci-
ties after corticosteroid treatment (prednisone 1 mg·kg-1
q.d. for 2–4 weeks).
As a control group, 24 healthy nonsmokers were stud-
ied; this group consisted of 14 males and 10 females,
aged 37–58 yrs (mean±SD 56±14 yrs).
Cell isolation and preparation
Bronchoalveolar lavage was performed using the method
described previously [19].  Briefly, informed consent was
obtained from each subject; after a pretreatment with
parental atropine sulphate (0.5 mg), the airways were
anaesthetized with 2% lidocaine.  A fibreoptic broncho-
scope (Olympus BF-1T10) was advanced and wedged
into either the middle lobe (controls) or into the radio-
logically affected segments or lobes (IEP patients) under
direct visualization.  Lavage was carried out with 200
mL of prewarmed (37˚C) sterile saline solution in ten 20
mL aliquots, with immediate gentle vacuum (syringe)
aspiration after each injection.  The total amount of fluid
recovered was measured (always >60% of injected saline);
the first aliquot recovered was examined separately for
cytological  and bacteriological studies, and the rest were
pooled.  Immediately after lavage, the fluid was filtered
though two layers of sterile surgical gauze.  Cells were
separated from the lavage fluid by centrifugation in a
Haeraeus Minifuge-T refrigerated centrifuge (4˚C, 20
min, 900 rpm) and washed in balanced salt solution (phos-
phate buffered saline (PBS) Serva).  Total cell count and
viability evaluation (trypan blue dye exclusion test) were
performed on a Bürker haemocytometer; differential cell
count was carried out on Diff-Quick (Don Baxter) stained
cytospin smears, counting at least 400 cells.   Immediately
before BAL, peripheral blood samples were obtained
from each patient and control subject by venipuncture:
10 mL vacuum sterile test tubes containing lithium hep-
arin (Vacutainer, BD) were employed.  Lymphocytes
were separated by centrifugation of blood samples after
stratification on density gradient (Lymphoprep, Nyegaard)
for 20 min at 1,000 rpm.  Simultaneously, haemochro-
mocytometric assay was performed (Technicon Hematology
System H3) to evaluate total and differential count of
white blood cells.
Phenotypic studies
Nonadherent cells were obtained by 1 h incubation at
37˚C in humidified 5% CO2 atmosphere (Haeraeus auto-
zero incubator), either from whole cellular BAL pellet
or mononuclear cells from peripheral blood, washed twice
in PBS and resuspended in sterile RPMI 1640 (Serva)
in sterile 250 mL polystyrene flasks (Falcon).  Phenotypic
characteristics were evaluated by employing a panel of
commercially available monoclonal antibodies (table 1)
and flow-cytometry (Facsan, Becton-Dickinson).  Standard
staining procedure [20] and single or two-colour analysis
with Facscan software (Becton-Dickinson) were used (at
least 5,000 events were assumed for each sample).
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Table 1.  –  CD, characteristics, specificity, and source of monoclonal antibodies employed
CD Commercial Specificity
CD3 Anti-Leu 4 * Mature T-lymphocytes
CD4 Anti-Leu 3 * Helper-inducer T-lymphocytes
CD8 Anti-Leu 2 * Suppressor-cytotoxic T-lymphocytes
CD25 Anti-IL2R * p55 IL-2 receptor
CD49a Anti-VLA-1 # β-intergrin; late-activated, not
proliferating T-lymphocytes
CD45RA Anti-Leu18 * Isoform of common leucocyte
antigen; naive T-lymphocytes
CD45R0 Anti-UCHL1 * Isoform of common leucocyte
antigen; memory T-lymphocytes
CD62L Anti-Leu 8 * L-selectin; adhesion molecule
Anti-HLA-DR * MHC class II-related antigen
CD45 Anti-HLe-1 * Pan-leucocyte
CD14 Anti-LeuM3 * Monocytes
*: Source Becton-Dickinson (Mountain View, CA, USA); #: source T-Cell Science (Cambride, MA, USA). IL-2: interleukin-2;
VLA-1: very late activation antigen-1; HLA-DR: human leucocyte antigen-DR; MHC: major histocompatibility complex.
Lymphocyte gates were obtained by using linear forward
angle light scatter; the lymphocyte gates were validated
by employing CD45-fluorescein-conjugated (pan-leuco-
cyte) and CD14 phycoerythrin-conjugated (monocyte)
monoclonal antibodies [20].  The lymphocyte population
was defined as CD45bright CD14negative; more than 95%
of all lymphocytes in each sample was contained with-
in the boundaries of the lymphocyte light-scatter gate.
Statistical analysis
Data are expressed as mean±standard error of the mean
(SEM): results obtained were analysed by Mann-Whitney-
Test.  A p-value of less than 0.05 was considered sta-
tistically significant.
Results
All samples from IEP patients showed no growth of
Gram-positive or Gram-negative bacteria, mycobacteria,
or fungi.  More than 95% of cells recovered were viable
in all samples studied.  Total and differential cell counts
in patients  with IEP showed, when compared to healthy
controls, a mild alveolitis (2.9±0.3 vs 1.8±0.1 ×105
cells·mL-1 p<0.001), an increase both of eosinophil per-
centage (49±1 vs 0%; p<0.001) and eosinophil absolute
number (141.2±34.4 vs 0 ×103 cells·mL-1; p<0.001).
Neutrophil percentage, as well as total count, showed a
mild but significant increase in IEP patients when com-
pared to healthy controls (3.0±0.5 vs 0.9±0.4%, respec-
tively; p<0.008; and 11.1±1.6 vs 1.1±0.4 ×103 cells·mL-1,
respectively; p<0.001).  No significant changes in lym-
phocyte mean percentage were seen (9.7±1.8 vs 6.7±1.3%;
p=NS).  The absolute number of alveolar lymphocytes
was significantly increased, being about three times more
than in healthy controls (27.7±5.1 vs 10.8±2.3 ×103
cells·mL-1; p<0.03).
CD3+, CD4+ and CD8+ alveolar lymphocytes were
evaluated either as a percentage of positive cells or as
absolute number of positive cells per millilitre fluid (table
2).  When data were expressed as percentage of positive
cells, CD3+ lymphocytes were higher in healthy controls
than in IEP patients, whereas no significant differences
of CD4+ and CD8+ subsets were observed.  Consequently,
no significant changes of the CD4/CD8 ratio were observed,
even in the presence of a slight increase of this ratio in
IEP patients.  When results were expressed as number
of positive cells ×103·mL-1 recovery fluid, an increase in
CD3+ cells, related to a high number both of CD4+ and
CD8+ lymphocytes could be seen in IEP patients
The coexpression of activation antigens were referred
and analysed either as percentage of all lymphocytes
(table 3) or as absolute count (cells ×103·mL-1 recovered
fluid) (table 4).  When data were expressed as percent-
age of positive cells of all lymphocytes an increase of
CD25 expression on CD4+ lymphocytes was observed
(16.1±2.7 vs 3.3±1%; p<0.001).  When data were expressed
as a number of positive cells ×103·mL-1 recovered fluid
we found a similar increased coexpression of CD25 on
CD4+ lymphocytes (2.8±0.7 vs 0.7±0.4 ×103 cells·mL-1;
p<0.05).  CD8+ lymphocytes, on the contrary, did not
show significant differences regarding the expression both
of CD25 and CD49a activation antigens (percentage and
total cell number).  The evaluation of coexpression on
CD4+ alveolar lymphocytes of CD45R0 and CD45RA
(tables 3 and 4) showed the percentage and, in particular,
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Table 2.  –  Percentage and absolute number of BAL
CD3+, CD4+, CD8+ lymphocyte subsets in IEP patients
and in control group
IEP Healthy p-values
patients controls
CD3+
Cells  % 83±1 91±1 <0.003
Cells  ×103·mL-1 25.0±7.5 9.9±1.8 <0.01
CD4+
Cells  % 53±6 51±2 NS
Cells  ×103·mL-1 16.7±6.8 5.5±1.0 <0.02
CD8+
Cells  % 31±11 37±2 NS
Cells  ×103·mL-1 8.4±1.9 4.2±0.8 <0.04
CD4/CD8 ratio 2.1±0.7 1.5±0.2 NS
Data are presented as percentage of all lymphocytes and as
number of positive lymphocytes ×103·mL-1 (mean±SEM).  BAL:
bronchoalveolar lavage; IEP: idiopathic eosinophilic pneumo-
nia; NS: nonsignificant.
Table 3.  –  Percentage of BAL CD3+, CD4+, and CD8+
lymphocytes expressing HLA-DR, CD25, CD49a, CD45R0,
CD45RA, and CD26L in IEP patients and in control group
IEP Healthy  P-values 
patients controls
CD3+/HLA-DR+ 25±5 16±2 NS
CD4+/CD25+ 16±3 3±1 0.001
CD4+/CD49a+ 13±2 7±2 NS
CD4+/CD62L+ 2±1 3±0.6 NS
CD4+/CD62L- 55±8 45±1.9 NS
CD4+/CD45R0+ 55±8 47±3 NS
CD4+/CD45RA+ 2±1 6±1 NS
CD8+/CD25+ 2±1 2±1 NS
CD8+/CD49a+ 13±1 16±1 NS
Data are presented as percentage of positive lymphocytes
(mean±SEM).  For abbreviations see legend to table 2.
Table 4.  –  Absolute number of BAL CD3+, CD4+, and
CD8+ lymphocytes expressing HLA-DR, CD25, CD49a,
CD45R0, CD45RA, and CD62L in IEP patients and in
control group
IEP Healthy  P-values 
patients controls
CD3+/HLA-DR+ 4±1.3 2.5±0.7 NS
CD4+/CD25+ 2.8±0.7 0.7±0.4 <0.05
CD4+/CD49a+ 2.8±2 1.2±0.8 NS
CD4+/CD62L+ 0.4±0.3 0.3±0.1 NS
CD4+/CD62L- 15.8±8.7 4.1±0.6 <0.02
CD4+/CD45R0+ 15.9±8.6 4.7±1 <0.03
CD4+/CD45RA+ 0.6±0.3 0.8±0.2 NS
CD8+/CD25+ 0.4±0.2 0.2±0.1 NS
CD8+/CD49a+ 2.8±1.2 2.8±0.1 NS
Data are presented as number of positive lymphocytes ×103
mL-1 (mean±SEM).  For abbreviations see legend to table 2.
the number (15.9±8.6 vs 4.7±1 ×105 cells·mL-1; p<0.03)
of memory (CD45R0+) T-cells in IEP was higher than
in controls.  Both low percentage and number of
CD4+/CD45RA+ lymphocytes was observed in patients
with IEP.  In patients with IEP, an increase of CD4+/CD62L-
lymphocytes, which was significant when evaluated as
absolute cell number (15.8±8.7 vs 4.1±0.6 ×105 cells·mL-1;
p<0.03), was observed (table 4).
In the peripheral blood of IEP patients, eosinophils
were significantly higher than in controls (3.2±0.9 vs
0.4±0.1 ×103 cells·µL-1, respectively; p<0.006) and only
a significant increase of CD4/CD25+ lymphocytes was
observed (0.2±0.05 vs 0.11±0.01 ×103 cells·µL-1; p<0.02)
(table 5–6).
Discussion
We demonstrated that patients with symptomatic IEP,
when compared to healthy nonsmoking subjects, were
characterized by an increase in total cells, eosinophils
and lymphocytes in BAL fluid.  The higher number of
alveolar CD3+ cells was related both to CD4+ and CD8+
subsets.  The analysis of expression of CD45R0 and
CD45RA, the two isoforms of a common leucocyte anti-
gen preferentially expressed, respectively, on primed (via
T-cell receptor) and on unprimed T-lymphocytes, and of
L-selectin CD62L, which enables T-cells to adhere to a
ligand expressed on high endothelium venules (HEV),
showed that the alveolitis of IEP patients was character-
ized by an accumulation of CD4+ lymphocytes expressing a
memory phenotypic repertoire (CD45R0+, CD45RA-,
CD62L-) [21–23].  In addition, accumulation of CD4+
alveolar lymphocytes showing a phenotypic pattern
typical of lymphokine-secreting cell, characterized by the
expression of early (CD25) activation antigens, was
observed in IEP patients.
In the peripheral blood, only a slight increase of
eosinophils was observed, accompanied by a less rele-
vant accumulation of CD4+/CD25+ lymphocytes.  These
differences may be explained either by the preferential
accumulation of different cell populations in different tis-
sues and organs [18], or by the ability of activated
eosinophils to act as antigen presenting cells for T-lym-
phocytes [24], leading to a self-maintaining mechanism
of lung eosinophilic inflammation.
A similar increase in CD4+/CD25+ lymphocytes both
in BAL and in peripheral blood has been observed [21]
in allergic asthma, an eosinophil-mediated airway dis-
ease, and the number of alveolar CD4+/CD25+ cells was
shown to correlate with the number of eosinophils and
the severity of disease [25].
As far as the CD8+ lymphocyte subsets were con-
cerned, there was a significant increase of total number
of CD8+ cells, without any significant difference of acti-
vation antigen expression, suggesting that suppressor/
cytotoxic T-lymphocytes are not actively involved in
immunomodulation of idiopathic eosinophil-mediated
lung disease.
In summary, we found in patients with symptomatic
idiopathic eosinophilic pneumonia, an accumulation of
alveolar CD3+ T-lymphocytes, both of CD4 and CD8+
subsets.  The CD4+ helper/inducer T-lymphocytes exhib-
ited the surface antigens typically associated with either
activated or memory T-lymphocytes.  Both activated and
memory T-lymphocyte subsets may be involved in the
modulation of eosinophilic inflammation in the alveolar
spaces.
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